Let us help you navigate
your prostate cancer concerns.
PCSANM members are survivors
who are here to answer your questions.
Our office is open 10 a.m. – 2 p.m. Monday – Thursday.
Due to COVID-19, all support group meetings remain
web-based. Please call or email for information on
meetings or to arrange for free, one-on-one support.
The next annual conference will be web-based and is scheduled for November 7 and 14, 2020
in Albuquerque, NM.
Our bi-weekly meetings are now virtual:
email us for more information on how to participate.
Free Library & Resources
We have a library with helpful books and information in our office. Due to COVID-19, our office is closed until further notice, but we are available to provide support by phone and to share resources by mail.
Approximately 1 in 7 men will get prostate cancer.
PCSANM helps all interested individuals and their families who are involved in coping with this disease.
- Publications and other reading materials on a wide variety of prostate cancer subjects
- Free one-on-one consultations for those diagnosed with prostate cancer and those dealing with the diagnosis of a loved one
- A list of survivors willing to discuss their treatment experience and side effects
- Bi-monthly support meetings including presentations by medical professionals expert in prostate cancer and related topics
- Outreach activities at conferences and health fairs
- Educational presentations to organizations
- Vouchers for free PSA tests for those who have no medical insurance, no primary care physician, or are experiencing troubling symptoms
We offer education, information, and support and will share our experiences with prostate cancer treatments and side effects.
Is one of these tests right for you? Do you even need one?
Antiandrogens continue to be focus of non-metastatic castrate-resistant prostate cancer (nmCRPC) treatment
Light shed on the nmCRPC treatment landscape and notable ongoing trials examining antiandrogens in different settings
Paul L. Nguyen, MD, discusses the role of radiation in high-risk prostate cancer and ongoing research efforts.